QuVa Pharma, Inc, a newly formed national platform for sterile compounding pharmacy services, acquired the assets of Unique Pharmaceuticals, Ltd, including its 503B manufacturing facility. With the acquisition, QuVa Pharma is addressing supply shortage issues that routinely and adversely impact the industry, and are securing significant, immediately available capacity in a second location. Unique Pharmaceuticals’ modern 503B manufacturing facility in Temple, Texas, recently underwent extensive modification, including installation of closed, restricted-access barrier compounding units designed to minimize the risk of product contamination by operators. All products produced at the facility undergo complete USP <71> testing for sterility, potency, and endotoxins before delivery to customers. QuVa Pharma expects to retain all current employees at the Unique Pharmaceuticals facility, and to integrate the operations with its existing 503B manufacturing facility located in Sugar Land, Texas.